SARS-CoV-2 Antigen Rapid Qualitative Test Type A

SARS-CoV-2 Antigen Rapid Qualitative Test Type B

ICE-100E Incubation Chamber

The incubation chamber is an auxiliary device for Biotime’s fluorescence immunoassay analyzer. The reaction temperature and time is critical for test results. The incubation chamber provides an optimized environment as well as automatic timers for test reactions to improve the reliability of test results.

LH Rapid Quantitative Test (Chemiluminescence Immunoassay)

LH Rapid Quantitative Test (Chemiluminescence Immunoassay) is used for in vitro quantitative detection of the Luteinizing hormone (LH) concentration in human serum and plasma that contains heparin /EDTA and other anticoagulants samples, mainly used for auxiliary diagnosis of reproductive hormones diseases.

MAU Rapid Quantitative Test

MAU(Microalbumin) occurs when the kidney leaks small amounts of albumin into the urine, which is an early marker of kidney damage.

PCT Rapid Quantitative Test (Chemiluminescence Immunoassay)

PCT Rapid Quantitative Test (Chemiluminescence Immunoassay) is used for in vitro quantitative detection of the Procalcitonin concentration in human serum, plasma that contains heparin /EDTA and other anticoagulants and venous whole blood samples, mainly used for auxiliary diagnosis of inflammation diseases.

CEA Rapid Quantitative Test

Carcinoembryonic antigen (CEA) is a protein normally found in very low levels in the blood of adults. The CEA blood level may be increased in certain types of cancer and non-cancerous (benign) conditions. A CEA test is most commonly used for colorectal cancer.

5 in 1 (cTnI/ CK-MB/ Myo/ NT-proBNP/ D-Dimer) Rapid Quantitative Test

Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain, suspected Acute Coronary Syndrome(ACS) and Heart Failure(HF), etc.

SARS-CoV-2 Antigen Rapid Qualitative Test

The SARS-CoV-2 Antigen Rapid Qualitative Test is a colloidal gold immunochromatography intended for the qualitative detection of nucleocapsid antigens from SARS-CoV-2 in human nasal swabs, throat swabs, and sputum from individuals who are suspected of COVID-19 by their healthcare provider. within the first five days of the onset of symptoms.

Solutions

Covid-19 Solution

SARS-CoV-2 Antigen Rapid Test

SARS-CoV-2 Antigen Rapid Qualitative Test Type A